$451 Million is the total value of Sarissa Capital Management LP's 10 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | BIOGEN INC. | $138,982,000 | -14.8% | 461,858 | 0.0% | 30.80% | -14.4% | |
| INVA | Buy | INNOVIVA INC. | $88,141,000 | +27.5% | 5,051,100 | +11.4% | 19.53% | +28.1% |
| AGN | Buy | ALLERGAN PLC | $73,045,000 | +11.5% | 546,500 | +58.9% | 16.19% | +12.0% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC. | $64,773,000 | +4.2% | 6,252,300 | +85.7% | 14.35% | +4.7% |
| MDCO | Buy | MEDICINES CO. | $53,228,000 | -7.4% | 2,781,000 | +44.7% | 11.80% | -7.0% |
| PBYI | New | PUMA BIOTECHNOLOGY INC. | $27,330,000 | – | 1,343,000 | +100.0% | 6.06% | – |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS INC. | $5,442,000 | -83.3% | 54,000 | -79.0% | 1.21% | -83.2% |
| SHPG | SHIRE PLCsponsored adr | $174,000 | -3.9% | 1,000 | 0.0% | 0.04% | -2.5% | |
| ABBV | ABBVIE INC. | $92,000 | -2.1% | 1,000 | 0.0% | 0.02% | -4.8% | |
| MRTX | New | MIRATI THERAPEUTICS INC. | $42,000 | – | 1,000 | +100.0% | 0.01% | – |
| NVLNF | Exit | NOVELION THERAPEUTICS INC. | $0 | – | -1,025,000 | -100.0% | -0.67% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.